BECHARA BARRAK: Open Payments
NPI 1912928177 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,358 in 155 payments from 36 companies in 2025. Trend: 2023 $3,964 · 2024 $3,888 · 2025 $3,358
Food & beverage: $3,258Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $479 |
| AstraZeneca Pharmaceuticals LP | 13 | $311 |
| GlaxoSmithKline, LLC. | 12 | $249 |
| Exact Sciences Corporation | 8 | $174 |
| Novartis Pharmaceuticals Corporation | 5 | $145 |
| Actelion Pharmaceuticals US, Inc. | 3 | $135 |
| Ardelyx, Inc. | 7 | $135 |
| Vanda Pharmaceuticals Inc. | 5 | $123 |
| Esperion Therapeutics, Inc. | 6 | $119 |
| E.R. Squibb & Sons, L.L.C. | 5 | $118 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, BREZTRI, UBRELVY, OPSUMIT, IBSRELA, QULIPTA, VRAYLAR.
Industry payments across CT — which companies pay providers there.
